Results 171 to 180 of about 5,687 (195)

Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage

Biomedicine and Pharmacotherapy, 2020
Mohamed E Shaker, Hesham A M Gomaa, Mohammad M Al-Sanea   +2 more
exaly  

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Lancet, The, 2018
Michael Wang, Simon A Rule, Pier Luigi Zinzani   +2 more
exaly  

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Lancet Haematology,the, 2020
Simon A Rule, Olivier Tournilhac, Francesco Forconi   +2 more
exaly  

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2016
Bonnie K Harrington, Susan M O'brien, Anna Schuh   +2 more
exaly  

<p>Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data</p>

Cancer Management and Research, 2020
Krista M Isaac
exaly  

Acalabrutinib

Reactions Weekly, 2019
openaire   +1 more source

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Clinical Therapeutics, 2020
Matthew S Davids, Pauline Le Nouveau, Gautamjeet Mangat   +2 more
exaly  

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

New England Journal of Medicine
Jennifer R Brown, Árpád Illés, Alessandra Tedeschi   +2 more
exaly   +2 more sources

Acalabrutinib — a new option in CLL

Nature Reviews Clinical Oncology, 2020
exaly  

Acalabrutinib/ibrutinib

Reactions Weekly, 2023
openaire   +1 more source